AstraZeneca Mexico – Ugo de Jacobis, President
AstraZeneca’s global strategic objectives are to achieve scientific leadership, to return to growth and to be a great place to work. The newly appointed president of the Mexico subsidiary discusses…
AstraZeneca is one of only a handful of pure-play biopharmaceutical companies to span the entire value chain of a medicine from discovery, early- and late-stage development to manufacturing and distribution, and the global commercialisation of primary care, specialty care-led and specialty care medicines that transform lives. The company focuses on three important areas of healthcare: Cardiovascular and Metabolic disease (CVMD); Oncology; and Respiratory, Inflammation and Autoimmunity (RIA). It is also active in the Infection, Neuroscience and Gastrointestinal (ING) disease areas. In Mexico the company relies on manufacturing capabilities and a staff of 150 people.
Contact details
AstraZeneca S.A. de C.V.
Periférico Sur No. 4305, 5to piso
Col. Jardines de la Montaña, Del. Tlalpan
CP 14210 México DF
MEXICO
Tel: +52 (55) 5374 9600
Website: www.astrazeneca.com/mexico
AstraZeneca’s global strategic objectives are to achieve scientific leadership, to return to growth and to be a great place to work. The newly appointed president of the Mexico subsidiary discusses…
There have been a lot of changes in the Mexican pharmaceutical industry in the last four to five years, most notably the new drug registration process being put in place.…
In July 2012 COFEPRIS (the Federal Commission for the Protection against Sanitary Risk) was recognized as a national regulatory authority of regional reference by the PAHO (Pan-American Health Organization), opening…
The founder of this spin-off of the Autonomous University of the State of Morelos focusing on biologicals for human and veterinary use offers an overview of how the company came…
Latin America continues to be in the spotlight at Grünenthal. The managing director for Mexico explains how the company is strengthening its product portfolio, working with stakeholders to create more…
The president of CETIFARMA, the council created by the pharmaceutical industry in Mexico for ethics and transparency, discusses the tireless effort it has made to professionalize the compliance function in…
The Mexico country manager of the Swiss biopharmaceutical company discusses the recent restructuring process the subsidiary has been going through, the strategic importance of Mexico as a logistic and clinical…
The executive director of the board bringing together multinational and local drug manufacturers talks about the chamber’s goal to position the pharmaceutical industry as the most important manufacturing sector in Mexico,…
Exactly 10 years ago Mexico realized that its public healthcare provision was inadequate as it was based on a system of employment benefits. This left over 50 million Mexicans…
Marked socio-economic differences in Mexico are playing an important role in pushing the uptake of generics, and these issues are starting to affect multinational corporations (MNCs). MNCs are being forced…
“As Mexicans we must be prepared for a new stage of our country’s development”. These were the inspiring words of newly elected Mexican President Peña Nieto, who has promised…
A Regulatory Overview of the Mexican Healthcare market by ALEJANDRO LUNA FANDIÑO, Partner Olivares & Cia. Olivares & Cia T +52 55 5322 3080 F +52 55 5322 3001 E…
Beyond the bright lights of Mexico City’s Santa Fe and Polanco districts, roughly half of Mexicans lack access to quality healthcare or medicines. This presents a challenge for pharma companies…
In the late 1990s, Rodrigo Herrera Aspra wanted to commercialize a new anti-acne formulation, and was advised by a friend who was involved in the pharmaceutical industry to hire a…
See our Cookie Privacy Policy Here